Skip to main content
. 2021 Jan 21;13(2):136. doi: 10.3390/pharmaceutics13020136

Figure 3.

Figure 3

(A) Relative ALP activity in MC3T3-E1 cells after treatment with free SV (100 nM), HP-β-CD/SV inclusion complexes (SV: 100 nM, HP-β-CD: 1 μM), and RM-β-CD/SV inclusion complexes (SV: 100 nM, RM-β-CD: 1 μM) for 14 days. (B) Relative ALP activity in MC3T3-E1 cells after treatment with free SV (100 nM), HP-β-CD (1 μM), and RM-β-CD (1 μM) for 14 days. Data are expressed as the mean ± S.D. (n = 3, * p < 0.05). Reproduced with permission from [74] © 2016 Elsevier.